DOCSLIB.ORG

Anti-Integrin Therapy for Inflammatory Bowel Disease S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anti-Integrin Therapy for Inflammatory Bowel Disease S View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Hofstra Northwell Academic Works (Hofstra Northwell School of Medicine) Donald and Barbara Zucker School of Medicine Journal Articles Academic Works 2018 Anti-integrin therapy for inflammatory bowel disease S. C. Park Zucker School of Medicine at Hofstra/Northwell Y. T. Jeen Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles Part of the Ophthalmology Commons Recommended Citation Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. 2018 Jan 01; 24(17):Article 3452 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/3452. Free full text article. This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact [email protected]. Submit a Manuscript: http://www.f6publishing.com World J Gastroenterol 2018 May 7; 24(17): 1868-1880 DOI: 10.3748/wjg.v24.i17.1868 ISSN 1007-9327 (print) ISSN 2219-2840 (online) MINIREVIEWS Anti-integrin therapy for inflammatory bowel disease Sung Chul Park, Yoon Tae Jeen Sung Chul Park, Division of Gastroenterology and Hepatology, Abstract Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon 24289, South Korea In inflammatory bowel disease (IBD), tumor necro­ sis factor plays an important role in mediating infla­ Yoon Tae Jeen, Division of Gastroenterology and Hepatology, mmation, but several other pathways are also involved Department of Internal Medicine, Korea University Anam Hospital, in eliciting an inflammatory response. One such Korea University College of Medicine, Seoul 02841, South Korea pathway is the invasion of the intestinal mucosa by leukocytes. Leukocytes within the systemic circulation ORCID number: Sung Chul Park (0000-0003-3215-6838); move to sites of inflammation, and blocking this Yoon Tae Jeen (0000-0003-0220-3816). pathway could be an important treatment strategy for IBD. Anti­integrin therapy blocks the action of Author contributions: Park SC and Jeen YT wrote the integrin on the surface of circulating immune cells and manuscript and made the tables and figures. endothelial cell adhesion molecules, thereby inhibiting Conflict­of­interest statement: Authors declare no conflict of the interactions between leukocytes and intestinal blood interests for this article. vessels. Natalizumab, which acts on α4­integrin, was the first such drug to be approved for Crohn’s disease, Open­Access: This article is an open-access article which was but its use is limited due to the risk of progressive selected by an in-house editor and fully peer-reviewed by external multifocal leukoencephalopathy. Vedolizumab produces reviewers. It is distributed in accordance with the Creative few systemic adverse effects because it acts on gut­ Commons Attribution Non Commercial (CC BY-NC 4.0) license, trophic α4β7 integrin, and has been approved and is which permits others to distribute, remix, adapt, build upon this being used to treat IBD. Currently, several anti­integrin work non-commercially, and license their derivative works on drugs, including etrolizumab, which acts on β7­integrin, different terms, provided the original work is properly cited and and PF­00547569, which targets mucosal addressin cell the use is non-commercial. See: http://creativecommons.org/ adhesion molecule­1, are undergoing clinical trials and licenses/by-nc/4.0/ the results are being closely watched. Manuscript source: Invited manuscript Key words: Integrin; Ulcerative colitis; Crohn’s disease; Correspondence to: Yoon Tae Jeen, MD, PhD, Professor, Natalizumab; Abrilumab; Etrolizumab; PF­00547659; Division of Gastroenterology and Hepatology, Department of Inflammatory bowel disease; AJM300; Vedolizumab Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, © The Author(s) 2018. Published by Baishideng Publishing Seoul 02841, South Korea. [email protected] Group Inc. All rights reserved. Telephone: +82-2-9206555 Fax: +82-2-9531943 Core tip: Anti­integrin therapies have attracted attention as new therapeutic agents in inflammatory bowel dis­ Received: March 23, 2018 ease. They inhibit the extravasation of leukocytes by Peer­review started: March 25, 2018 First decision: April 18, 2018 blocking the interaction between integrins on immune Revised: April 23, 2018 cells and endothelial cell adhesion molecules. The use Accepted: April 26, 2018 of the first developed anti­integrin agent, natalizumab Article in press: April 26, 2018 is now limited due to the risk of progressive multifocal Published online: May 7, 2018 leukoencephalopathy. However, vedolizumab which acts WJG|www.wjgnet.com 1868 May 7, 2018|Volume 24|Issue 17| Park SC et al . Anti­integrin therapy for IBD selectively on the gut has shown few adverse events tokines define and regulate various aspects of the infla­ and is currently used in clinical practice. Newer anti­ mmatory response and play an important role in the integrin drugs that act on different integrins­related pathogenesis of IBD including Crohn’s disease (CD) targets, such as AJM300, abrilumab, etrolizumab, and and ulcerative colitis (UC), with the former mediated PF­00547659 have also been developed and are in by type 1 T helper cells (TH1) and TH17, and the latter clinical trials. reportedly caused by an abnormal TH2 response. The immunopathogenesis of IBD is made more complex Park SC, Jeen YT. Anti-integrin therapy for inflammatory by imbalances in different T cell subsets, such as bowel disease. World J Gastroenterol 2018; 24(17): 1868-1880 regulatory T cells, natural killer T cells, and TH9, as Available from: URL: http://www.wjgnet.com/1007-9327/full/ well as the interactions between these cell populations. v24/i17/1868.htm DOI: http://dx.doi.org/10.3748/wjg.v24. Ultimately, the production of numerous cytokines is i17.1868 disturbed. These cytokines include the well­known TNF­α as well as IL­1β, IL­6, IL­8, IL­10, IL­12, IL­17, IL­23, and transforming growth factor­α[3,6]. The use of TNF antagonists showed that just blocking INTRODUCTION a single cytokine could be sufficient to induce significant clinical remission. Until recently, in moderate­to­severe Causes of inflammatory bowel disease (IBD) have not active IBD patients, especially if initial treatment with yet been clearly elucidated, but it is known that genetic systemic corticosteroids or immunomodulators failed, susceptibility, altered gut microbiota, and environmental anti­TNF agents were the only remaining treatment factors are all involved. It has also been reported that option. a combination of these factors causes an inappropriate Inspired by the treatment outcomes of the first immune response, resulting in impaired intestinal generation anti­TNF agent infliximab, next­generation barrier function[1-3]. TNF antagonists, such as adalimumab, golimumab, As continual research further reveals the immuno­ and certolizumab pegol, were introduced for the treat­ pathogenesis of IBD, the treatment of IBD has shifted ment of IBD, drastically changing this treatment field; from conventional treatments, such as aminosalicylates, however, even these drugs did not show an effect in glucocorticoids, and immunomodulators (thiopurines all IBD patients. Specifically, although reports differ and methotrexate), toward the biological drugs that [4] slightly, anti­TNF agents produce primary non­response target inflammation­related pathways . Anti­tumor (PNR) in approximately 10%­30% of patients[7]. Several necrosis factor (TNF) agents were the first biologics factors have been suggested as causes of PNR. One used to treat IBD, and the objective of IBD treatment known cause of PNR is that TNF is not a major factor in has shifted from controlling symptoms to changing the progression of disease and preserving the intestinal the development of inflammation in some patients, and therefore, there is an increased need for drugs with new function. However, anti­TNF agents are not effective in [8] all IBD patients, and a considerable number of patients mechanisms . experience relapse after stopping medication. The Although anti­TNF agents show an initial effect, pathophysiology of IBD is very complex. This means secondary non­response or loss of response (LOR) is [7,9] that the most appropriate treatment method may vary seen in 23%­46% . LOR is known to occur due to for each patient, and therefore, constant efforts are pharmacokinetic issues or the production of antibodies being made to develop effective drugs[4]. In particular, against the drug; however, it can also be caused by a new biologics that inhibit leukocyte trafficking to the shift in the inflammatory response pathway from TNF site of inflammation have been developed and used. signaling to non­TNF signaling. Moreover, due to their These drugs are called anti­integrin or anti­adhesion comprehensive immunosuppressive effects, the use of agents, or leukocyte­trafficking inhibitors because anti­TNF agents can cause severe adverse reactions, they block the actions of integrin, a cell surface protein including tuberculosis (TB), hepatitis B, pneumonia, expressed by circulating immune cells and endothelial herpes zoster, and other infections, as well as skin cell adhesion molecules (CAMs), thereby selectively
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • Biological Treatments in Inflammatory Bowel Disease: a Complex Mix Of
    Review Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions Lorena Ortega Moreno 1,2,3 , Samuel Fernández-Tomé 1,3 and Raquel Abalo 4,5,6,7,* 1 Instituto de Investigación Sanitaria Hospital Universitario de La Princesa, 28006 Madrid, Spain; [email protected] (L.O.M.); [email protected] (S.F.-T.) 2 Department of Medicine, Faculty of Medicine, Universidad Autónoma de Madrid, 28049 Madrid, Spain 3 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 Madrid, Spain 4 Department of Basic Health Sciences, Faculty of Health Sciences, University Rey Juan Carlos (URJC), 28922 Alcorcón, Spain 5 High Performance Research Group in Physiopathology and Pharmacology of the Digestive System (NeuGut-URJC), URJC, 28922 Alcorcón, Spain 6 Associated I+D+i Unit to the Institute of Medicinal Chemistry (IQM), Scientific Research Superior Council (CSIC), 28006 Madrid, Spain 7 Working Group of Basic Sciences in Pain and Analgesia of the Spanish Pain Society (Grupo de Trabajo de Ciencias Básicas en Dolor y Analgesia de la Sociedad Española del Dolor), 28046 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-91-488-8854 Abstract: Inflammatory bowel disease (IBD) is a chronic disease that requires lifelong medication and whose incidence is increasing over the world. There is currently no cure for IBD, and the current ther- apeutic objective is to control the inflammatory process. Approximately one third of treated patients do not respond to treatment and refractoriness to treatment is common. Therefore, pharmacological Citation: Moreno, L.O.; treatments, such as monoclonal antibodies, are urgently needed, and new treatment guidelines are Fernández-Tomé, S.; Abalo, R.
    [Show full text]
  • The Current State of the Art for Biological Therapies and New Small Molecules in Inflammatory Bowel Disease
    www.nature.com/mi REVIEW ARTICLE The current state of the art for biological therapies and new small molecules in inflammatory bowel disease Sudarshan Paramsothy1, Adam K. Rosenstein1,2, Saurabh Mehandru1,2 and Jean-Frederic Colombel1 The emergence of biologic therapies is arguably the greatest therapeutic advance in the care of inflammatory bowel disease (IBD) to date, allowing directed treatments targeted at highly specific molecules shown to play critical roles in disease pathogenesis, with advantages in potency and selectivity. Furthermore, a large number of new biologic and small-molecule therapies in IBD targeting a variety of pathways are at various stages of development that should soon lead to a dramatic expansion in our therapeutic armamentarium. Additionally, since the initial introduction of biologics, there have been substantial advances in our understanding as to how biologics work, the practical realities of their administration, and how to enhance their efficacy and safety in the clinical setting. In this review, we will summarize the current state of the art for biological therapies in IBD, both in terms of agents available and their optimal use, as well as preview future advances in biologics and highly targeted small molecules in the IBD field. Mucosal Immunology (2018) 11:1558–1570; https://doi.org/10.1038/s41385-018-0050-3 INTRODUCTION concerns regarding the safety of these agents have decreased Inflammatory bowel disease (IBD) incorporates a spectrum of with accumulating data. Although there is a slightly increased risk chronic, often progressive and disabling, inflammatory disorders of serious infections, this is lower than initially predicted and less of the gastrointestinal tract including Crohn’s disease (CD) and than the risk associated with steroid use.12 Concerns regarding ulcerative colitis (UC).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]
  • 211 the Impact of Biological Interventions on Health-Related Quality of Life in Adults with Crohn's Disease
    211 The impact of biological interventions on health-related quality of life in adults with Crohn's disease The impact of biological interventions on health-related quality of life in adults with Crohn's disease Protocol information Review type: Intervention Review number: 211 Authors Mirjana Stanic Benic1, Vanja Giljaca2, Vera Vlahovic-Palcevski1 1Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Rijeka, Croatia 2Directorate of Surgery, Department of Gastroenterology, Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham, UK Citation example: Stanic Benic M, Giljaca V, Vlahovic-Palcevski V. The impact of biological interventions on health- related quality of life in adults with Crohn's disease. Cochrane Database of Systematic Reviews , Issue . Art. No.: . DOI: . Contact person Mirjana Stanic Benic resident in clinical pharmacology and toxicology Department of Clinical Pharmacology Clinical Hospital Centre Rijeka Krešimirova 42 Rijeka 51000 Croatia E-mail: [email protected] Dates Assessed as Up-to-date:Not provided Date of Search: Not provided Next Stage Expected: 28 February 2019 Protocol First Published:Not specified Review First Published: Not specified Last Citation Issue: Not specified What's new Date Event Description History Date Event Description Abstract Background Objectives Search methods Selection criteria Data collection and analysis Main results Authors' conclusions Plain language summary [Summary title] [Summary text] Background Description of the condition 1 / 20 211 The impact of biological interventions on health-related quality of life in adults with Crohn's disease Crohn’s disease (CD) is a relapsing-remitting transmural inflammatory bowel disease (IBD) that may involve any part of the gastrointestinal tract from mouth to anus as well as cause extraintestinal manifestations (skin lesions, arthritis).
    [Show full text]
  • New Targets in Inflammatory Bowel Disease Therapy: 2021
    REVIEW CURRENT OPINION New targets in inflammatory bowel disease therapy: 2021 Nathaniel A. Cohen and David T. Rubin Purpose of review In the rapidly progressing world of inflammatory bowel disease, this review discusses and summarizes new drug targets and results from major clinical trials in order to provide an update to physicians treating patients with inflammatory bowel diseases (IBD). Recent findings Multiple new mechanisms in the treatment of IBD are being developed and many are showing promising results in both ulcerative colitis and Crohn’s disease patients. In addition to efficacy, some of these treatments may provide safety benefits over existing therapies. Summary The IBD physicians’ therapeutic armamentarium is rapidly expanding and keeping abreast of these developments is required in order to provide patients with optimized individualized care. Keywords biologics, inflammatory bowel disease, new therapeutics, small molecules INTRODUCTION physician’s armamentarium, a significant percentage The inflammatory bowel diseases (IBD) are a hetero- of patients do not respond to these treatments [10]. geneous group of conditions divided into two As such, new treatment pathways and a greater predominant groups, Crohn’s disease (CD) and ulcer- understanding of mechanisms of treatment failure ative colitis (UC). These conditions are characterized are required. This will provide more options for by a chronic, progressive, or relapsing and remitting patients and greater individualization in treatment disease course with the gastrointestinal (GI) tract decision-making. being the major site of inflammatory activity. This review examines the future of IBD treat- Unchecked, this inflammation can result in a ments and details current phase I, II, and III clinical complicated disease course with undesirable ramifi- trial results.
    [Show full text]
  • Ulcerative Colitis and Probiotics: an Overview
    REVIEW Ulcerative colitis and probiotics: An overview Irfan Ahmad Rather1, Rajib Majumder1, Fanar Hamad Alshammari1, Jae Gyu Park2 and Vivek Kumar Bajpai1* 1Department of Applied Microbiology and Biotechnology, School of Biotechnology, Yeungnam University, Gyeongsan, Gyeongbuk, Korea 2Pohang Technopark, Pohang Center for Evaluation of Biomaterials, Jigok-ro, Nam-gu, Pohang, Gyeongbuk, Korea Abstract: Ulcerative colitis is an inflammatory disease of the large intestine whose effects are bloody diarrhea, cramping and bloating. The disease is usually relapsing and remitting. However, the cause of ulcerative colitis is not yet known. Due to this reason, finding an effective treatment has been a great challenge. The suggested medical treatment is usually composed of two portions; keeping the flare up from happening and treating the flare up when it has happened. Active flare ups are treated with corticosteroids. There are several hypothesis which suggest that ulcerative colitis could be due to the micro flora present in gut. For this reason, several researchers tried to modify the gut microflora with probiotics. However, there is no probiotics found that can induce emission faster than the placebo. The ulcerative colitis patients taking probiotics showed fewer and less severe symptoms during the flare up. This means that even though the probiotics did not end up the flare up faster, it slowed up the severity of the symptoms of the patients. Keywords: Ulcerative colitis, inflammation, probiotics. INTRODUCTION important in digestion and also prevent other types of bacteria from occupying their spaces. This is the basic Ulcerative colitis (UC) is a chronic disease which is concept of the probiotics referred to as the good bacteria.
    [Show full text]